Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by FDA panel

Go back to Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by FDA panel

Novavax's (NVAX) Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC

June 9, 2022 10:16 AM EDT

The U.S. Food and Drug Administration's (FDA) decision on Novavax's (NASDAQ: NVAX) Covid-19 vaccine could be delayed, according to a report by CNBC.

An FDA spokesperson told CNBC that the regulatory body will have to review modifications to the drugmakers... More

Novavax (NVAX) Covid Vaccine Wins Backing of FDA Panel in Vote of 20 to 0 with 1 Abstain

June 7, 2022 3:30 PM EDT

Novavax (NASDAQ: NVAX) Covid Vaccine Wins Backing of FDA Panel in Vote of 20 to 0 with 1 Abstain

... More